Likewise, we showed that TERT mutations, which are rare in lung cancer (approximate prevalence of 2%) and have been correlated with poor prognosis, are enriched in NSCLC patients harboring class 2 and 3 BRAF alterations and are absent in V600E mutants, which constituted the totality of class 1 patients [70]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.